Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

Abstract Background and Aim Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first‐line treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF and continuous ETV monotherapy in patients with mainta...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Atsushi Hiraoka, Keizo Kato, Hiroshi Abe, Shigeru Mikami, Noritomo Shimada, Makoto Chuma, Akito Nozaki, Haruki Uojima, Chikara Ogawa, Toru Asano, Joji Tani, Asahiro Morishita, Tomonori Senoh, Naoki Yamashita, Tsunekazu Oikawa, Yoshihiro Matsumoto, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Ai‐Nakagawa Iwashita, Chisa Kondo, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Katsuhiko Iwakiri
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2021-01-01
Ráidu:	JGH Open
Fáttát:	entecavir hepatitis B surface antigen nucleos(t)ide analogs tenofovir alafenamide
Liŋkkat:	https://doi.org/10.1002/jgh3.12443
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!